A Phase 3 interventional study of fezolinetant and placebo in Hot Flashes, sponsored by Astellas Pharma Global Development, Inc.. Completed at 182 sites in 8 countries. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-05.
Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing fezolinetant in Hot Flashes — 4 open to participants now, 5 under way, 4 of them phase 3. fezolinetant · Hot Flashes.
Among the 16 studies testing fezolinetant in Hot Flashes, this one has the largest enrollment, is one of 3 that started in 2019, is one of 10 in phase 3, and was the 2nd registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →4 of the 16 studies testing fezolinetant in Hot Flashes are open now, in 2 countries. Recruiting first, the newest first:
Astellas Pharma Inc · Sites in India
Ages 18+ · Women only
University of Colorado, Denver · Sites in United States
Ages 45–55 · Women only · Healthy volunteers
University of Vermont · Sites in United States
Ages 18+ · Men only
Rebecca Thurston · Sites in United States
Ages 40–65 · Women only
By country, each count listing its studies:
fezolinetant: first FDA approval 2023 (VEOZAH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 40 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 11
First in 2015; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,831 is above the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 249 across the 16 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 16 have an industry lead sponsor. The 7 most frequent:
This study is registered under Astellas Pharma Global Development, Inc., one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.
Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.
16 studies in Hot Flashes by Astellas Pharma Inc: 2 open now, 3 under way, 2 of them phase 3. Of 13 finished, 5 (38%) have results posted.
Among the 16 studies in Hot Flashes by Astellas Pharma Inc, this one has the largest enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2019, is one of 9 in phase 3, and was the 2nd registered.
Astellas Pharma Inc’s Hot Flashes studies by the year they started, since 2015.
1 of the studies testing fezolinetant in Hot Flashes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972875University of VermontFezolinetant for Treating Hot Flashes in Men With Prostate Cancer | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing fezolinetant in Hot Flashes, from their registry updates:
Among Astellas Pharma Inc’s 16 in Hot Flashes:
This tab as a report to print or save as PDF → With an account.
This study was for women in menopause with hot flashes. Menopause, a normal part of aging, was the time of a woman's last period. Hot flashes can interrupt a woman's daily life.
The purpose of this study was to find out how safe it is for these women to take fezolinetant in long term (up to 52 weeks). To do that, the study looked at the number and severity of the "adverse events." Those were the side effects that study participants had while they were in the study.
The study treatments were fezolinetant 30 milligrams (mg) (1 tablet of fezolinetant and 1 placebo tablet) once a day, fezolinetant 45 mg (2 tablets of fezolinetant) once a day or placebo (2 tablets) once a day. (Placebo was a dummy treatment that looked like medicine but did not have any medicine in it.) Women in this study were picked for 1 of the 3 study treatments by chance alone. The study participants took study treatment for 52 weeks.
This study was "double-blinded." That means that the study participants and the study doctors did not know who took which of the study treatments (fezolinetant 30 mg, fezolinetant 45 mg or placebo).
At weeks 2 and 4 and then once a month, the study participants went to the hospital or clinic for a check-up. They were asked about medications, side effects and how they felt. Other checks included physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine were collected for laboratory tests. At some study visits, study participants completed questionnaires that were about their quality of life. At the first and last study visits, they had a dual-energy x-ray absorptiometry (DXA for short) test done. To measure bone loss in the hips and spine, DXA created pictures of the inside of these areas with low-dose x-rays. (The dose was approximately one-tenth of the amount of a normal chest x-ray.) Study participants who still had their uterus had 2 more tests done at the first and last study visits. One of the 2 tests was endometrial biopsy. This test involved removing a small amount of tissue from the inside lining of the uterus. The tissue was then checked under a microscope. The other test was transvaginal ultrasound. It used sound waves to create pictures of the organs in the pelvis. The sound waves were transmitted by a probe (transducer), which was placed inside the vagina. Study participants might have had a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not had this test done in the last 12 months had it done at the first study visit. They had done at the last study visit if they were due for their screening mammogram and their own doctor agreed.
The last check-up at the hospital or clinic was at 3 weeks after the last dose of study treatment.
This study consisted of a screening period and a 52 week treatment period. Safety follow up occurred 3 weeks after the last dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject must be seeking treatment or relief for vasomotor symptoms (VMS) associated with menopause and confirmed as menopausal per 1 of the following criteria at the screening visit:
Exclusion Criteria:
Subject's systolic blood pressure is ≥ 130 mmHg or diastolic blood pressure is ≥ 80 mmHg based on the average of 2 to 3 readings, on at least 2 different occasions within the screening period.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received fezolinetant 30 mg (one 30 mg fezolinetant tablet and one placebo tablet) orally, once daily (QD) for a period of 52 Weeks.
Drug: fezolinetant
Participants received fezolinetant 45 mg (one 30 mg tablet and one 15 mg tablet) orally, QD for a period of 52 Weeks.
Drug: fezolinetant
Participants received fezolinetant matching placebo (two fezolinetant matching placebo tablets) orally, QD for a of period of 52 Weeks.
Drug: placebo
administered orally
administered orally
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a participant administered a study drug, \& which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable \& unintended sign, symptom, or disease temporally associated with the use of medicinal product (MP) whether or not considered related to MP. An AE is considered "serious" if it results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires inpatient hospitalization or leads to prolongation of hospitalization, hospitalization for treatment/observation/examination caused by AE is to be considered as serious, discontinuation due to increases in liver enzymes, other medically important events. A TEAE is defined as an AE observed after starting administration of study drug \& 21 days after the last dose of study drug.
Time frame: From first dose of study drug until 21 days after last dose of study drug (Up to 55 weeks)
Number of Participants With Mild, Moderate and Severe TEAE
An adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product. A TEAE is defined as an AE observed after starting administration of the study drug and 21 days after the last dose of study drug. Severity of AE we were classified as Mild: No disruption of normal daily activities; Moderate: Affect normal daily activities; and Severe: Inability to perform daily activities.
Time frame: From first dose of study drug until 21 days after last dose of study drug (Up to 55 weeks)
Percentage of Participants With Endometrial Hyperplasia
Endometrial hyperplasia was confirmed from the endometrial biopsy report.
Time frame: Baseline Up to 52 weeks
Percentage of Participants With Endometrial Cancer
Endometrial cancer was confirmed from the endometrial biopsy report.
Time frame: Baseline Up to 52 weeks
Change From Baseline in Endometrial Thickness at Week 52
Endometrial thicness was obtained from the transvaginal ultrasound. The endometrium was measured in the long axis or sagittal plane. The measurement was of the thickest echogenic area from 1 basal endometrial interface across the endometrial canal to the other basal surface.
Time frame: Baseline and week 52
Percentage of Participants With Disordered Proliferative Endometrium
Disordered proliferative endometrium was confirmed from the endometrial biopsy report.
Time frame: Baseline Up to 52 weeks
Change From Baseline in Bone Mineral Density (BMD) at Hip at Week 52
Changes in BMD hip was assessed by dual-energy X-ray absorptiometry (DXA) scan.
Time frame: Baseline and week 52
Change From Baseline in Trabecular Bone Score (TBS) at Hip at Week 52
TBS was a bone texture assessment that serves as a substitute for bone microarchitecture and predicts fracture risk independent of BMD and clinical risk factors. The DXA imaging was processed and analyzed as it would normally be and then evaluated using an automated algorithm to determine the TBS. T-score ≥1.350 was considered to be normal; T-score between 1.200 and 1.350 is considered to be consistent with partially degraded microarchitecture; and T-score ≤1.200 defines degraded microarchitecture.
Time frame: Baseline and week 52
Change From Baseline in BMD at Spine at Week 52
Changes in BMD spine was assessed by DXA scan.
Time frame: Baseline and week 52
Change From Baseline in TBS at Spine at Week 52
TBS was a bone texture assessment that serves as a substitute for bone microarchitecture and predicts fracture risk independent of BMD and clinical risk factors. The DXA imaging was processed and analyzed as it would normally be and then evaluated using an automated algorithm to determine the TBS. T-score ≥1.350 was considered to be normal; T-score between 1.200 and 1.350 is considered to be consistent with partially degraded microarchitecture; and T-score ≤1.200 defines degraded microarchitecture.
Time frame: Baseline and week 52
Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
The C-SSRS assessed the risk for suicidal behavior and suicide ideation. Participants responded as "Yes" or "No" 10 items. Suicidal ideation (1. Wish to be dead; 2. Non-specific active suicidal thoughts; 3. Active suicidal ideation with any methods (not plan) without intent to act; 4. Active suicidal ideation with some intent to act, without specific plan; 5. Active suicidal ideation with specific plan and intent; ). Suicidal behaviour (1. Preparatory acts or behavior 2. Aborted attempt 3. Interrupted attempt 4. Actual attempt 5. Completed suicide). Participants with 'Yes' to any one of the above 10 questions for suicidal ideation and behavior were reported.
Time frame: Baseline, week 12, week 24, week 52 and follow-up (week 55)
Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS
The C-SSRS assessed the risk for Self-injurious Behavior without Suicidal Intent. Question was asked "Has participant engaged in Non-Suicidal Self-Injurious Behavior?". Participants with 'yes' to the question were reported.
Time frame: Baseline, week 12, week 24, week 52 and follow-up (week 55)
Female participants aged ≥ 40 and ≤ 65 years seeking treatment for vasomotor symptoms (VMS) associated with menopause and who met the inclusion criteria and none of the exclusion criteria were enrolled in this study.
| Milestone | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg |
|---|---|---|---|
| Started | 611 | 611 | 609 |
| Treated | 610 | 611 | 609 |
| Completed | 410 | 451 | 444 |
| Not completed | 201 | 160 | 165 |
| Withdrew: Adverse event | 27 | 34 | 28 |
| Withdrew: Lost to follow-up | 39 | 30 | 33 |
| Withdrew: Protocol violation | 1 | 6 | 5 |
| Withdrew: Withdrawal by subject | 119 | 79 | 85 |
| Withdrew: Miscellaneous | 14 | 11 | 14 |
| Withdrew: Participant did not receive study drug | 1 | 0 | 0 |
An AE is any untoward medical occurrence in a participant administered a study drug, \& which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable \& unintended sign, symptom, or disease temporally associated with the use of medicinal product (MP) whether or not considered related to MP. An AE is considered "serious" if it results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires inpatient hospitalization or leads to prolongation of hospitalization, hospitalization for treatment/observation/examination caused by AE is to be considered as serious, discontinuation due to increases in liver enzymes, other medically important events. A TEAE is defined as an AE observed after starting administration of study drug \& 21 days after the last dose of study drug.
| participants | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg |
|---|---|---|---|
| TEAE | 391 | 415 | 389 |
| Drug-Related TEAE | 106 | 94 | 110 |
| Serious TEAE | 14 | 20 | 23 |
| Drug-Related Serious TEAE | 1 | 0 | 0 |
| TEAE Leading to Death | 0 | 1 | 0 |
| Drug-Related TEAE Leading to Death | 0 | 0 | 0 |
| TEAE Leading to Withdrawal of Treatment | 26 | 34 | 28 |
| Drug-Related TEAE Leading to Withdrawal of Treatment | 16 | 16 | 17 |
| Death | 0 | 1 | 0 |
An adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product. A TEAE is defined as an AE observed after starting administration of the study drug and 21 days after the last dose of study drug. Severity of AE we were classified as Mild: No disruption of normal daily activities; Moderate: Affect normal daily activities; and Severe: Inability to perform daily activities.
| participants | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg |
|---|---|---|---|
| Mild | 180 | 215 | 195 |
| Moderate | 191 | 185 | 171 |
| Severe | 20 | 15 | 23 |
Endometrial hyperplasia was confirmed from the endometrial biopsy report.
| percentage of participants | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg |
|---|---|---|---|
| Percentage of Participants With Endometrial Hyperplasia | 0 | 0 | 0.5 |
Endometrial cancer was confirmed from the endometrial biopsy report.
| percentage of participants | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg |
|---|---|---|---|
| Percentage of Participants With Endometrial Cancer | 0 | 0.5 | 0 |
Endometrial thicness was obtained from the transvaginal ultrasound. The endometrium was measured in the long axis or sagittal plane. The measurement was of the thickest echogenic area from 1 basal endometrial interface across the endometrial canal to the other basal surface.
| millimeter (mm) | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg |
|---|---|---|---|
| Change From Baseline in Endometrial Thickness at Week 52 | -0.17 ± 2.35 | -0.15 ± 1.97 | -0.28 ± 2.30 |
Disordered proliferative endometrium was confirmed from the endometrial biopsy report.
| percentage of participants | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg |
|---|---|---|---|
| Percentage of Participants With Disordered Proliferative Endometrium | 2.2 | 1.4 | 0 |
Changes in BMD hip was assessed by dual-energy X-ray absorptiometry (DXA) scan.
| gram per square centimeter (g/cm^2) | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg |
|---|---|---|---|
| Hip (Femoral Neck) | -0.010 ± 0.033 | -0.001 ± 0.044 | -0.009 ± 0.033 |
| Hip (Femur) | -0.011 ± 0.022 | -0.003 ± 0.041 | -0.008 ± 0.024 |
| Hip (Trochanter) | -0.008 ± 0.027 | -0.001 ± 0.042 | -0.004 ± 0.026 |
TBS was a bone texture assessment that serves as a substitute for bone microarchitecture and predicts fracture risk independent of BMD and clinical risk factors. The DXA imaging was processed and analyzed as it would normally be and then evaluated using an automated algorithm to determine the TBS. T-score ≥1.350 was considered to be normal; T-score between 1.200 and 1.350 is considered to be consistent with partially degraded microarchitecture; and T-score ≤1.200 defines degraded microarchitecture.
| T-Score (Index) | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg |
|---|---|---|---|
| Hip (Femoral Neck) | -0.078 ± 0.246 | -0.011 ± 0.372 | -0.073 ± 0.265 |
| Hip (Femur) | -0.085 ± 0.192 | -0.024 ± 0.354 | -0.063 ± 0.192 |
| Hip (Trochanter) | -0.071 ± 0.255 | -0.009 ± 0.426 | -0.036 ± 0.246 |
Changes in BMD spine was assessed by DXA scan.
| g/cm^2 | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg |
|---|---|---|---|
| Change From Baseline in BMD at Spine at Week 52 | -0.013 ± 0.035 | -0.010 ± 0.049 | -0.014 ± 0.034 |
TBS was a bone texture assessment that serves as a substitute for bone microarchitecture and predicts fracture risk independent of BMD and clinical risk factors. The DXA imaging was processed and analyzed as it would normally be and then evaluated using an automated algorithm to determine the TBS. T-score ≥1.350 was considered to be normal; T-score between 1.200 and 1.350 is considered to be consistent with partially degraded microarchitecture; and T-score ≤1.200 defines degraded microarchitecture.
| T-Score (Index) | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg |
|---|---|---|---|
| Change From Baseline in TBS at Spine at Week 52 | -0.117 ± 0.296 | -0.084 ± 0.025 | -0.119 ± 0.298 |
The C-SSRS assessed the risk for suicidal behavior and suicide ideation. Participants responded as "Yes" or "No" 10 items. Suicidal ideation (1. Wish to be dead; 2. Non-specific active suicidal thoughts; 3. Active suicidal ideation with any methods (not plan) without intent to act; 4. Active suicidal ideation with some intent to act, without specific plan; 5. Active suicidal ideation with specific plan and intent; ). Suicidal behaviour (1. Preparatory acts or behavior 2. Aborted attempt 3. Interrupted attempt 4. Actual attempt 5. Completed suicide). Participants with 'Yes' to any one of the above 10 questions for suicidal ideation and behavior were reported.
| participants | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg |
|---|---|---|---|
| Baseline | 2 | 2 | 4 |
| Week 12 | 0 | 0 | 1 |
| Week 24 | 1 | 1 | 2 |
| Week 52 | 1 | 0 | 0 |
| Follow-up (Week 55) | 0 | 1 | 2 |
The C-SSRS assessed the risk for Self-injurious Behavior without Suicidal Intent. Question was asked "Has participant engaged in Non-Suicidal Self-Injurious Behavior?". Participants with 'yes' to the question were reported.
| participants | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg |
|---|---|---|---|
| Baseline | 0 | 1 | 0 |
| Week 12 | 1 | 0 | 0 |
| Week 24 | 0 | 0 | 0 |
| Week 52 | 0 | 0 | 0 |
| Follow-up (Week 55) | 1 | 0 | 0 |
Collected over From first dose of study drug until 21 days after last dose of study drug (Up to 55 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/610 (0%) | 14/610 (2.3%) | 90/610 (14.8%) |
| Fezolinetant 30 mg | 1/611 (0.2%) | 20/611 (3.3%) | 86/611 (14.1%) |
| Fezolinetant 45 mg | 0/609 (0%) | 23/609 (3.8%) | 78/609 (12.8%) |
| Event | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg |
|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/610 | 1/611 | 2/609 |
| COVID-19Infections and infestations | 1/610 | 0/611 | 2/609 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/610 | 0/611 | 2/609 |
| Endometrial adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/610 | 1/611 | 2/609 |
| GoitreEndocrine disorders | 0/610 | 1/611 | 1/609 |
| PancreatitisGastrointestinal disorders | 0/610 | 0/611 | 1/609 |
| VomitingGastrointestinal disorders | 0/610 | 0/611 | 1/609 |
| Chest painGeneral disorders | 0/610 | 0/611 | 1/609 |
| InfluenzaInfections and infestations | 1/610 | 0/611 | 1/609 |
| MeningitisInfections and infestations | 0/610 | 0/611 | 1/609 |
| Event | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg |
|---|---|---|---|
| HeadacheNervous system disorders | 56/610 | 52/611 | 54/609 |
| COVID-19Infections and infestations | 37/610 | 38/611 | 30/609 |
All randomized participants.
| Age, Continuous(Years) | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg | Total |
|---|---|---|---|---|
| Mean | 54.8 ± 4.8 | 54.7 ± 4.7 | 54.7 ± 4.8 | 54.7 ± 4.8 |
| Sex: Female, Male(Participants) | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg | Total |
|---|---|---|---|---|
| Female | 611 | 611 | 609 | 1831 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 133 | 118 | 116 | 367 |
| Not Hispanic or Latino | 478 | 493 | 491 | 1462 |
| Unknown or Not Reported | 0 | 0 | 2 | 2 |
| Race (NIH/OMB)(Participants) | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 3 | 2 | 8 |
| Asian | 8 | 8 | 13 | 29 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 92 | 114 | 110 | 316 |
| White | 502 | 479 | 479 | 1460 |
| More than one race | 6 | 6 | 4 | 16 |
| Unknown or Not Reported | 0 | 1 | 1 | 2 |
| Smoking status(participants) | Placebo | Fezolinetant 30 mg | Fezolinetant 45 mg | Total |
|---|---|---|---|---|
| Current | 117 | 116 | 116 | 349 |
| Former/Never | 494 | 495 | 493 | 1482 |
Showing the first 100 of 182 sites across 8 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data
Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Data sharing details ↗ · www.clinicaltrials.astellas.com
Ran from Jul 2019 to primary completion in Jan 2022, 29 months.
Results were first posted in Feb 2023, 1 year after primary completion.
Of 23 phase 3 interventional studies under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 29 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fezolinetant
Astellas Pharma Global Development, Inc. →